It is known that amyloid β42 and tau burden occur in a relatively large portion of non‐demented populations and are a risk factor for cognitive decline, mild cognitive impairment and Alzheimer's disease (Ebenau et al., 2020; Ingala et al., 2021). This evidence concerns the gene MAPT and Alzheimer disease.